af-001 / Alpha Fusion - LARVOL DELTA

Alpha Fusion…announced the initiation of a company-sponsored Phase I clinical trial (jRCT2031250472) of the alpha-emitting radiopharmaceutical af-001, which contains [²¹¹At]NaAt as its active pharmaceutical ingredient, in patients with differentiated thyroid cancer (papillary and follicular carcinoma) (PRNewswire-Asia) - "This clinical trial is designed based on the results of an investigator-initiated Phase I study conducted at The University of Osaka, and consists of Part Ia and Part Ib."

Trial status • Differentiated Thyroid Carcinoma • Thyroid Gland Follicular Carcinoma • Thyroid Gland Papillary Carcinoma